Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer Retraction in /10.3892/ol.2021.13061

Kato,Tomoya; Nakamori,Mikihito; Matsumura,Shuichi; Nakamura,Masaki; Ojima,Toshiyasu; Fukuhara,Hiroshi; Ino,Yasushi; Todo,Tomoki; Yamaue,Hiroki

doi:10.3892/ol.2021.12751

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer

Retraction in: /10.3892/ol.2021.13061

Authors:
- Tomoya Kato
- Mikihito Nakamori
- Shuichi Matsumura
- Masaki Nakamura
- Toshiyasu Ojima
- Hiroshi Fukuhara
- Yasushi Ino
- Tomoki Todo
- Hiroki Yamaue
View Affiliations

Affiliations: Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641‑8510, Japan, Department of Urology, Kyorin University, School of Medicine, Mitaka, Tokyo 181‑8611, Japan, Division of Innovative Cancer Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan
Published online on: April 23, 2021 https://doi.org/10.3892/ol.2021.12751
Article Number: 490
Copyright: © Kato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, gastric cancer is the third most common cause of cancer‑associated mortality worldwide. Oncolytic virotherapy using herpes simplex virus (HSV) has emerged as a novel therapeutic strategy against cancer. Telomerase is activated in >90of malignant tumors, including gastric cancer, and human telomerase reverse transcriptase (hTERT) is one of the major components of telomerase enzyme. Therefore, in oncolytic HSV, placing the essential genes under the regulation of the hTERT promoter may enhance its antitumor efficacy. The present study examined the antitumor effect of fourth‑generation oncolytic HSVs, which contain the ICP6 gene under the regulation of the hTERT promoter (T‑hTERT). To examine the association between hTERT expression and prognosis in patients with gastric cancer, immunohistochemical analysis of resected tumor specimens was performed. The enhanced efficacy of T‑hTERT was determined in human gastric cancer cell lines in vitro and in human gastric adenocarcinoma specimens in vivo. In in vitro experiments, enhanced cytotoxicity of T‑hTERT was observed in MKN1, MKN28 and MKN45 cells compared with that of a third‑generation oncolytic HSV, T‑null. In particular, the cytotoxicity of T‑hTERT was markedly enhanced in MKN45 cells. Furthermore, in vivo experiments demonstrated that 36.7 and 54.9% of cells were found to be lysed 48 h after infection with T‑null or T‑hTERT viruses at 0.01 pfu/cell, respectively. The T‑hTERT‑treated group exhibited considerably lower cell viability than the control [phosphate‑buffered saline (‑)] group. Therefore, employing oncolytic HSVs that contain the ICP6 gene under the regulation of the hTERT promoter may be an effective therapeutic strategy for gastric cancer. To the best of our knowledge, the present study was the first to describe the effect of an oncolytic HSV with ICP6 expression regulated by the hTERT promoter on gastric cancer cells.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
3	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hemminki A, Oksanen M and Merisalo-Soikkeli M: Oncolytic virotherapy trials-letter. Clin Cancer Res. 19:4541–4542. 2013. View Article : Google Scholar : PubMed/NCBI
5	Russell SJ, Peng KW and Bell JC: Oncolytic virotherapy. Nat Biotechnol. 30:658–670. 2012. View Article : Google Scholar : PubMed/NCBI
6	Maroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng KW and Russell S: Designing and building oncolytic viruses. Future Virol. 12:193–213. 2017. View Article : Google Scholar : PubMed/NCBI
7	Fukuhara H, Ino Y and Todo T: Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 107:1373–1379. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mineta T, Rabkin SD, Yazaki T, Hunter WD and Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1:938–943. 1995. View Article : Google Scholar : PubMed/NCBI
9	Delwar ZM, Liu G, Kuo Y, Lee C, Bu L, Rennie PS and Jia WW: Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Oncotarget. 7:28658–28669. 2016. View Article : Google Scholar : PubMed/NCBI
10	Longo SL, Griffith C, Glass A, Shillitoe EJ and Post DE: Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther. 18:123–134. 2011. View Article : Google Scholar : PubMed/NCBI
11	Lee CY, Bu LX, Rennie PS and Jia WW: An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther. 14:652–660. 2007. View Article : Google Scholar : PubMed/NCBI
12	Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K, Dishman DJ, et al: Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 23:3566–3574. 2017. View Article : Google Scholar : PubMed/NCBI
13	Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, et al: A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 22:1048–1055. 2014. View Article : Google Scholar : PubMed/NCBI
14	Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK and Tawfik H: Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 21:1119–1128. 2010. View Article : Google Scholar : PubMed/NCBI
15	Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 33:2780–2788. 2015. View Article : Google Scholar : PubMed/NCBI
16	Deguchi T, Shikano T, Kasuya H, Nawa A, Fujiwara S, Takeda S, Gewen T, Sahin TT, Yamada S, Kanzaki A, et al: Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers. Hepatogastroenterology. 59:1844–1850. 2012.PubMed/NCBI
17	Wong J, Kelly K, Mittra A, Gonzalez SJ, Song KY, Simpson G, Coffin R and Fong Y: A third-generation herpesvirus is effective against gastroesophageal cancer. J Surg Res. 163:214–220. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y and Todo T: Efficacy of a Third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncolytics. 17:205–215. 2020. View Article : Google Scholar : PubMed/NCBI
19	Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T and Yamaue H: An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer. 132:485–494. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N and Chi B: Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. Int J Mol Med. 30:747–754. 2012. View Article : Google Scholar : PubMed/NCBI
21	Yano S, Takehara K, Tazawa H, Kishimoto H, Urata Y, Kagawa S, Fujiwara T and Hoffman RM: Therapeutic cell-cycle-decoy efficacy of a telomerase-dependent adenovirus in an orthotopic model of chemotherapy-resistant human stomach carcinomatosis peritonitis visualized with FUCCI imaging. J Cell Biochem. 118:3635–3642. 2017. View Article : Google Scholar : PubMed/NCBI
22	Seimiya H: Crossroads of telomere biology and anticancer drug discovery. Cancer Sci. 111:3089–3099. 2020. View Article : Google Scholar : PubMed/NCBI
23	Zhang C, Chen X, Li L, Zhou Y, Wang C and Hou S: The association between telomere length and cancer prognosis: Evidence from a meta-analysis. PLoS One. 10:e01331742015. View Article : Google Scholar : PubMed/NCBI
24	Watson JD: Origin of concatemeric T7 DNA. Nat New Biol. 239:197–201. 1972. View Article : Google Scholar : PubMed/NCBI
25	Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA and Shay JW: Telomerase activity in human breast tumors. J Natl Cancer Inst. 88:116–122. 1996. View Article : Google Scholar : PubMed/NCBI
26	Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
27	Kyo S, Kanaya T, Ishikawa H, Ueno H and Inoue M: Telomerase activity in gynecological tumors. Clin Cancer Res. 2:2023–2028. 1996.PubMed/NCBI
28	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant tumours. 7th edition. Wiley-Blackwell; Hoboken, NJ, USA: 2011
29	Lü MH, Deng JQ, Cao YL, Fang DC, Zhang Y and Yang SM: Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis. Exp Ther Med. 3:728–734. 2012. View Article : Google Scholar
30	Campagna D, Cope L, Lakkur SS, Henderson C, Laheru D and Iacobuzio-Donahue CA: Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol. 1:32–43. 2008.PubMed/NCBI
31	Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, Zapata JM, Monks A, Scudiero DA, Bauknecht T and Reed JC: Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol. 158:1335–1344. 2001. View Article : Google Scholar : PubMed/NCBI
32	Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM and Grandis JR: Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res. 14:1303–1309. 2008. View Article : Google Scholar : PubMed/NCBI
33	Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S and Yamaue H: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
34	Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG and Edwards J: Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer. 99:1769–1774. 2008. View Article : Google Scholar : PubMed/NCBI
35	Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M: Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol. 130:58–64. 2008. View Article : Google Scholar : PubMed/NCBI
36	Todo T, Martuza RL, Rabkin SD and Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 98:6396–6401. 2001. View Article : Google Scholar : PubMed/NCBI
37	Fu X, Nakamori M, Tao L, Amato R and Zhang X: Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol. 30:1561–1567. 2007.PubMed/NCBI
38	Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M and Aburatani H: Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res. 13:5703–5709. 2007. View Article : Google Scholar : PubMed/NCBI
39	Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010. View Article : Google Scholar : PubMed/NCBI
40	Passer BJ, Wu CL, Wu S, Rabkin SD and Martuza RL: Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther. 16:1477–1482. 2009. View Article : Google Scholar : PubMed/NCBI
41	Nordlund P and Reichard P: Ribonucleotide reductases. Annu Rev Biochem. 75:681–706. 2006. View Article : Google Scholar : PubMed/NCBI
42	Hsieh YY, Chou CJ, Lo HL and Yang PM: Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer. Cell Death Discov. 2:160272016. View Article : Google Scholar : PubMed/NCBI
43	Eriksson S and Martin DW Jr: Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J Biol Chem. 256:9436–9440. 1981. View Article : Google Scholar : PubMed/NCBI
44	Chen CH and Chen RJ: Prevalence of telomerase activity in human cancer. J Formos Med Assoc. 110:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
45	Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Björkholm M, et al: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 32:4203–4213. 2013. View Article : Google Scholar : PubMed/NCBI
46	Ruden M and Puri N: Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 39:444–456. 2013. View Article : Google Scholar : PubMed/NCBI
47	Yoo J, Park SY, Kang SJ, Kim BK, Shim SI and Kang CS: Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas. Mod Pathol. 16:700–707. 2003. View Article : Google Scholar : PubMed/NCBI
48	Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y, et al: A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases. Clin Cancer Res. 19:6495–6505. 2013. View Article : Google Scholar : PubMed/NCBI
49	Watanabe M, Kagawa S, Kuwada K, Hashimoto Y, Shigeyasu K, Ishida M, Sakamoto S, Ito A, Kikuchi S, Kuroda S, et al: Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer. Cancer Sci. 109:3263–3271. 2018. View Article : Google Scholar : PubMed/NCBI
50	Ishikawa W, Kikuchi S, Ogawa T, Tabuchi M, Tazawa H, Kuroda S, Noma K, Nishizaki M, Kagawa S, Urata Y and Fujiwara T: Boosting replication and penetration of oncolytic adenovirus by paclitaxel eradicate peritoneal metastasis of gastric cancer. Mol Ther Oncolytics. 18:262–271. 2020. View Article : Google Scholar : PubMed/NCBI
51	Nakatake R, Kaibori M, Nakamura Y, Tanaka Y, Matushima H, Okumura T, Murakami T, Ino Y, Todo T and Kon M: Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci. 109:600–610. 2018. View Article : Google Scholar : PubMed/NCBI
52	Matsushima H, Kaibori M, Hatta M, Ishizaki M, Nakatake R, Okumura T, Yoshii K and Todo T: Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models. Oncotarget. 10:7132–7141. 2019. View Article : Google Scholar : PubMed/NCBI
53	Lam JT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Liu B, Wang M, Barnes MN, et al: Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med. 6:1333–1342. 2004. View Article : Google Scholar : PubMed/NCBI
54	Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell. 174:1031–1032. 2018. View Article : Google Scholar : PubMed/NCBI